AS per file enclosed.

Pat Growth 25pctEbitda Margin ExpansionResults View source PDF Explain this filing

VENUSREM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+5.1%Reaction day

₹1160.00

prior close

₹1219.10

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.0%+5.1% vs market

Pharmaceuticals peers, median of 164sector+0.1%+5.0% vs sector

On the reaction day the stock moved 5.1 pts more than Nifty Microcap 250 and 5.0 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.0

10m

+0.0

15m

+0.0

30m

+0.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+5.1-0.0+5.1+0.1+5.0

Next day

+10.3-0.7+11.0-0.6+10.9

+15.9-1.8+17.6-1.3+17.2

+21.7-0.7+22.4-1.4+23.1

+27.7-0.5+28.2-1.6+29.3

+34.1+0.4+33.7-0.6+34.7

+41.9-1.6+43.5-2.3+44.2

15d

+48.5+4.6+43.9+0.0+48.5

+66.3+4.6+61.7+3.0+63.3

+35.6+6.1+29.4+4.3+31.3

+37.9+10.8+27.1+8.6+29.4

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 164Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Venus Remedies reported strong FY2026 results with standalone revenue from operations of Rs. 768.73 crore, up 19.3% from Rs. 644.47 crore in FY2025. Net profit jumped 89% to Rs. 99.31 crore from Rs. 52.55 crore. Consolidated revenue was Rs. 769.60 crore with net profit of Rs. 102.78 crore, representing 127% PAT growth over the prior year. EBITDA margin improved significantly. The board recommended a final dividend of Rs. 10 per share (100%) subject to shareholder approval at the 37th AGM scheduled for August 20, 2026. Statutory auditors J.K. Jain & Associates issued an unmodified (clean) opinion on both standalone and consolidated financial statements.

Likely market impact

The company demonstrated robust double-digit revenue growth and exceptional profit expansion, indicating strong operational performance and cost efficiency. The clean audit opinion and dividend declaration are positive signals for shareholders. The stock may see positive reaction given the strong profitability growth.